Corporate | 9 December 2010 07:00
|
Cytos Biotechnology AG / Key word(s): Research Update
Bacterially produced Qb-Flu provides equivalent protection as commercial egg based influenza vaccine in standard industry model Schlieren (Zurich), Switzerland, and Amsterdam, NL, December 9, 2010 – Cytos Biotechnology Ltd (SIX:CYTN) today presents new results from preclinical studies with the Influenza vaccine candidate Qb-Flu at the World Influenza Congress Europe 2010 in Amsterdam, The Netherlands. Qb-Flu is a bacterially produced subunit vaccine composed of the globular domain of the Influenza A hemagglutinin surface protein conjugated to Cytos' virus-like particle Qb. The vaccine candidate was developed in collaboration with the Experimental Therapeutics Centre and the Singapore Immunology Network, institutes under Singapore's Agency for Science, Technology and Research (A*STAR). In the present study, conducted in collaboration with the 'Institut national de la recherche scientifique' (INRS Canada), Qb-Flu was tested side-by-side with Panvax(R), an approved egg-based Influenza H1N1 A/California/07/09 vaccine in ferrets, the standard animal model for the preclinical assessment of vaccine efficacy. Qb-Flu and Panvax(R) both induced high levels of virus neutralizing antibodies after only a single injection. These titers were further increased after the second immunization. The level of virus neutralizing antibodies induced by Qb-Flu was slightly higher than that induced by the commercial vaccine Panvax(R). As expected, control ferrets, which had not been immunized, developed strong signs of disease after infection with Influenza virus. In stark contrast, Qb-Flu and Panvax(R) treated animals were almost completely protected against disease, thus demonstrating that Qb-Flu provides equivalent protection to Panvax(R) in ferrets. These pivotal preclinical studies underscore the quality of the recombinant Qb-Flu vaccine which is produced entirely in E. coli bacteria, enabling the rapid production of the large quantities needed in mass vaccination campaigns. Dr Martin Bachmann, CSO of Cytos Biotechnology commented 'We are very pleased that our Influenza vaccine candidate Qb-Flu performed so well in the industry-standard model for influenza infection. Furthermore, Qb-Flu is produced in a highly efficient bacterial fermentation process which provides significant production advantages over the traditional egg based or cell culture based approaches. Through our proprietary technology, we expect that it will be possible to rapidly produce large amounts of recombinant Qb-Flu in order to supply seasonal and pandemic vaccine markets.'
For further information please contact:
About Cytos Biotechnology
This foregoing press release may contain forward-looking statements that include words or phrases such as 'expect', 'will', 'designed', 'intended' or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd. End of Corporate News 09.12.2010 News transmitted by EquityStory AG. The issuer is responsible for the contents of the release. EquityStory publishes regulatory releases, media releases on the capital market and press releases. The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies. The Swiss news archive can be found at http://www.equitystory.ch/nachrichten |
| Language: | English | |
| Company: | Cytos Biotechnology AG | |
| Wagistr. 25 | ||
| 8952 Schlieren | ||
| Schweiz | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@cytos.com | |
| Internet: | www.cytos.com | |
| ISIN: | CH0011025217, CH0029060735 | |
| Swiss Security Number: | – | |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt | |
| End of News | EquityStory AG News-Service |
|
|
| 105932 09.12.2010 |